Expertise in
1
conditions

Dr. Aparna M. Hegde

Hematology
UAB Hospital Birmingham
619 19th St S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
UAB Hospital Birmingham
619 19th St S, 
Birmingham, AL 

Overview

Aparna Hegde is a Hematologist practicing medicine in Birmingham, Alabama.

Dr. Hegde is highly rated in 1 condition, according to our data. Her clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer and Anaplastic Large Cell Lymphoma.

She is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

UAB Hospital Birmingham
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Enrollment Status: Recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
View 5 Less Clinical Trials

34 Total Publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Office

1720 2nd Ave S, 
Birmingham, AL 
 (0.4 miles away)
205-996-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amitkumar Mehta is a Hematologist practicing medicine in Birmingham, Alabama. Dr. Mehta is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Mehta is currently accepting new patients.

Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Referral may be required

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist practicing medicine in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
22
conditions
Dr. Luciano Costa
Hematology | Oncology
Expertise in
22
conditions
Dr. Luciano Costa
Hematology | Oncology
Referral may be required

Hematology Oncology At The Kirklin Clinic Of Uab Hospital

2000 6th Ave S Fl 5, 
Birmingham, AL 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luciano Costa is a Hematologist and an Oncologist practicing medicine in Birmingham, Alabama. Dr. Costa is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Costa is currently accepting new patients.

Frequently Asked Questions about Dr. Aparna M. Hegde

How do I make an appointment with Dr. Aparna M. Hegde?

You can book an appointment with Dr. Aparna M. Hegde by calling their office at 205-934-4011. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aparna M. Hegde a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aparna M. Hegde is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aparna M. Hegde specialize in?

While Dr. Aparna M. Hegde is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Aparna M. Hegde participate in research or clinical trials?

Yes. Dr. Aparna M. Hegde has published 34 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Aparna M. Hegde's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aparna M. Hegde accept my insurance?

Dr. Aparna M. Hegde accepts most major insurance plans, including Humana and Wellcare. We recommend calling the office directly at 205-934-4011 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hegde's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile